Similarly, an ESK2 TCR-mimic antibody specific for Wilms tumor protein (WT1) presented by HLA-A*02 was coupled with a CD33-specific scFv (linked to CD28), demonstrating promising therapeutic effects against AML in vitro and in animal models [155]. This evidence concerns the gene CD33 and acute myeloid leukemia.